Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database. (23rd July 2021)
- Record Type:
- Journal Article
- Title:
- Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database. (23rd July 2021)
- Main Title:
- Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database
- Authors:
- Gartland, Margaret
Arnoult, Eric
Foley, Brian T
Lataillade, Max
Ackerman, Peter
Llamoso, Cyril
Krystal, Mark - Abstract:
- Abstract: Background: Fostemsavir, a prodrug of the gp120-directed attachment inhibitor temsavir, is indicated for use in heavily treatment-experienced individuals with MDR HIV-1. Reduced susceptibility to temsavir in the clinic maps to discrete changes at amino acid positions in gp160: S375, M426, M434 and M475. Objectives: To query the Los Alamos National Laboratory (LANL) HIV Sequence Database for the prevalence of polymorphisms at gp160 positions of interest. Methods: Full-length gp160 sequences ( N = 7560) were queried for amino acid polymorphisms relative to the subtype B consensus at positions of interest; frequencies were reported for all sequences and among subtypes/circulating recombinant forms (CRFs) with ≥10 isolates in the database. Results: Among 239 subtypes in the database, the 5 most prevalent were B ( n = 2651, 35.1%), C ( n = 1626, 21.5%), CRF01_AE ( n = 674, 8.9%), A1 ( n = 273, 3.6%) and CRF02_AG ( n = 199, 2.6%). Among all 7560 sequences, the most prevalent amino acids at positions of interest (S375, 73.5%; M426, 82.1%; M434, 88.2%; M475, 89.9%) were the same as the subtype B consensus. Specific polymorphisms with the potential to decrease temsavir susceptibility (S375H/I/M/N/T/Y, M426L/P, M434I/K and M475I) were found in <10% of isolates of subtypes D, G, A6, BC, F1, CRF07_BC, CRF08_BC, 02A, CRF06_cpx, F2, 02G and 02B. S375H and M475I were predominant among CRF01_AE (S375H, 99.3%; M475I, 76.3%; consistent with previously reported lowAbstract: Background: Fostemsavir, a prodrug of the gp120-directed attachment inhibitor temsavir, is indicated for use in heavily treatment-experienced individuals with MDR HIV-1. Reduced susceptibility to temsavir in the clinic maps to discrete changes at amino acid positions in gp160: S375, M426, M434 and M475. Objectives: To query the Los Alamos National Laboratory (LANL) HIV Sequence Database for the prevalence of polymorphisms at gp160 positions of interest. Methods: Full-length gp160 sequences ( N = 7560) were queried for amino acid polymorphisms relative to the subtype B consensus at positions of interest; frequencies were reported for all sequences and among subtypes/circulating recombinant forms (CRFs) with ≥10 isolates in the database. Results: Among 239 subtypes in the database, the 5 most prevalent were B ( n = 2651, 35.1%), C ( n = 1626, 21.5%), CRF01_AE ( n = 674, 8.9%), A1 ( n = 273, 3.6%) and CRF02_AG ( n = 199, 2.6%). Among all 7560 sequences, the most prevalent amino acids at positions of interest (S375, 73.5%; M426, 82.1%; M434, 88.2%; M475, 89.9%) were the same as the subtype B consensus. Specific polymorphisms with the potential to decrease temsavir susceptibility (S375H/I/M/N/T/Y, M426L/P, M434I/K and M475I) were found in <10% of isolates of subtypes D, G, A6, BC, F1, CRF07_BC, CRF08_BC, 02A, CRF06_cpx, F2, 02G and 02B. S375H and M475I were predominant among CRF01_AE (S375H, 99.3%; M475I, 76.3%; consistent with previously reported low temsavir susceptibility of this CRF) and 01B (S375H, 71.7%; M475I, 49.5%). Conclusions: Analysis of the LANL HIV Sequence Database found a low prevalence of gp160 amino acid polymorphisms with the potential to reduce temsavir susceptibility overall and among most of the common subtypes. … (more)
- Is Part Of:
- Journal of antimicrobial chemotherapy. Volume 76:Number 11(2021)
- Journal:
- Journal of antimicrobial chemotherapy
- Issue:
- Volume 76:Number 11(2021)
- Issue Display:
- Volume 76, Issue 11 (2021)
- Year:
- 2021
- Volume:
- 76
- Issue:
- 11
- Issue Sort Value:
- 2021-0076-0011-0000
- Page Start:
- 2958
- Page End:
- 2964
- Publication Date:
- 2021-07-23
- Subjects:
- Anti-infective agents -- Periodicals
Chemotherapy -- Periodicals
615.58 - Journal URLs:
- http://jac.oxfordjournals.org ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/jac/dkab257 ↗
- Languages:
- English
- ISSNs:
- 0305-7453
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4939.100000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25073.xml